Pneumocystis jirovecii infection: Cell wall (1→3)-β-D-glucan biology and diagnostic utility

Critical Reviews in Microbiology

Volumn 36, Issue 4, 2010, Pages 271-281

  Finkelman, Malcolm A ^a  

^a Associates of Cape Cod Inc   (United States)

Author keywords

Beta glucan; Diagnostic; Inflammation; Pneumocystis; Pneumonia

Indexed keywords

BETA 1,3 GLUCAN; DECTIN 1; INTERLEUKIN 23; INTERLEUKIN 6; LACTATE DEHYDROGENASE; MACROPHAGE INFLAMMATORY PROTEIN 2; PROTEIN KINASE SYK; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CELL WALL; FUNGAL CELL; FUNGAL LIFE CYCLE STAGE; HUMAN; IMMUNOMODULATION; LUNG LAVAGE; NONHUMAN; PATHOPHYSIOLOGY; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; REVIEW; TAXONOMY;

BETA-GLUCANS; CELL WALL; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; MALE; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; TOLL-LIKE RECEPTORS;

PNEUMOCYSTIS; PNEUMOCYSTIS JIROVECII;

EID: 77958018538     PISSN: 1040841X     EISSN: 15497828     Source Type: Journal    
DOI: 10.3109/1040841X.2010.484001     Document Type: Review

References (110)

1. Aliouat EM, Pottier M, Gantois N, Dei-Cas E. (2009). Te Pneumocystis life cycle. Mem Inst Oswaldo Cruz 104, 419-426.
2. Azoulay E, Bergeron A, Chevret S, Bele N, Schlemmer B, Menotti J. (2009). Polymerase chain reaction for diagnosing Pneumocystis pneumonia in non-HIV immunocompromised patients with pulmonary infltrates. Chest 135, 655-651.
3. Beard CR, Carter JL, Keely SP, Huang L, Pieniazek NJ, Moura INS, Roberts JM, Hightower AW, Bens MS, Freeman AR, Lee S, Stringer JR, Duchin JS, del Rio C, RimLand D, Baughman RP, Levy D, Dietz VJ, Simon P, Navin TR. (2000). Genetic variation in Pneumocystis carinii isolates from diferent geographic regions, Implications for transmission. Emerg Infect Dis 6, 265-272.
4. th anniversary summary. Euk Cell 8, 446-460.
5. Bowers GJ, Patchen ML, MacVittie TJ, Hirsch E F, Fink MP. (1986). A comparative evaluation of particulate and soluble glucan in an endotoxin model. Int Soc Immunopharm 8, 313-321.
6. Bryar JM, Hammond SP, Tolaney SM, Marty FM, Baden LR. (2009). Pneumocystis jirovecii pneumonia. (PCP). in patients with early stage (ES) breast cancer (BC). Poster K-950, Inter-Science Conference on Antimicrobial Agents and Chemotherapy, San Francisco.
7. Calderon EJ, Rivero L, Respaldiza N, Morilla R, Montes-Cano MA, Friaza V, Munoz-Lobato F, Varela JM, Medrano FJ, de la Horra C. (2007). Systemic infammation in patients with chronic obstructive pulmonary disease who are colonized with Pneumocystis jirovecii. Clin Infect Dis 45, e17-e19.
8. Chagas C. (1909). Nova trypanosomiaze human. Mem Instit Oswaldo Cruz 1, 159-218.
9. Cook JA, Dougherty WJ, Holt TM. (1980). Enhanced sensitivity to endotoxin induced by the RE stimulant, glucan. Circulatory Shock 7, 225-238.
10. Cordani S, Annunziata M, Vignali M, Tascini C. (2008). Bronchoalveolar lavage as a diagnostic tool in patients with hematological malignancies and pneumonia. Le Infezione in Medicina 4, 209-213.
11. Crothers K, Huang L. (2009). Pulmonary complications of immune reconstitution infammatory syndromes in HIV-infected patients. Respirology 14, 486-494.
12. Cuetara MS, Alhambra A, Chaves F, Moragues MD, Ponton J, del Palacio A. (2008). Use of a serum. (1→3).-β-D-glucan assay for diagnosis and follow-up of Pneumocystis jirovecii pneumonia. Clin Infect Dis 47, 1364-1366.
13. Cushion MT, Waltzer PD, Smulian AG, Linke MJ, Rufolo JJ, Kaneshiro ES, Stringer JR. (1997). Terminology for the life cycle of Pneumocystis carinii. Infect Immun 65, 4365.
14. Davis JL, Welsh DA, Beard CB, Jones JL, Lawrence GG, Fox MR, Crothers K, Morris A, Charbonnet D, Swartzman A, Huang L. (2008). Pneumocystis colonization is common among hospitalized HIV patients with non-Pneumocystis infection. Torax 63, 329-334.
15. De Souza W, Benchimol M. (2005). Basic biology of Pneumocystis carinii - A mini review. Mem Inst Oswaldo Cruz 100, 903-908.
16. Del Bono V Mularoni A, Furfaro E, Delfno E, Rosasco L, Miletich F, Viscoli C. (2009). Clinical evaluation of. (1,3).-ß-d-glucan assay in presumptive Pneumocystis jirovecii pneumonia in immunocompromised patients. Clin Vacc Immunol 16, 1524-1526.
17. Delanoe P, Delanoe M. (1912). Sur les rapports des kystes de Carinii du poumon des rats avec le trypanosome. Lewisii CR Acad Sci (Paris) 155, 658-570.
18. Dennehy KM, Ferwerda G, Faro-Trindade I, Pyz E, Willment JA, Taylor PR, Kerrigan A, Tsoni SV Gordon S, Meyer-Wentrup F, Adema GJ, Kullberg BJ, Schweighofer E, Tybulewicz V, Mora-Montes HM, Gow NA, Williams DL, Netea MG, Brown GD. (2008). Syk kinase is required for collaborative cytokine production induced through dectin-1 and toll-like receptors. Eur J Immunol 38, 500-506.
19. Dennehy KM, Willment JA, Williams DL, Brown GD. (2009). Reciprocal regulation of IL-23 and IL-12 following co-activation of Dectin-1 and TLR signaling pathways. Eur J Immunol 39, 1379-1386.
20. Desmet S, Van Wijngaerden E, Maertens J, Verhaegen J, Verbeken E, De Munter P, Meersseman W, Van Meensel B, Van Eldere J, Lagrou K. (2009). Serum (1-3)-{beta}-D-Glucan as a Tool for Diagnosis of Pneumocystis jirovecii Pneumonia in Patients with Human Immunodefciency Virus Infection or Hematological Malignancy. J Clin Microbiol 47, 3781-3784.
21. Divaret G, Magne D, Angoulvant A, Roux P. (2008). Usefulness of serum (1-3)-ß-D-glucan assay for Pneumocystis jirovecii pneumonia diagnosis Abstract P017, International Workshop on Opportunistic Protists, Boston, MA.
22. Dowdle WR. (1983). Te epidemiology of AIDS. Public Health Reports 98, 308-312.
23. Durand-Joly I, Soula F, Dalle JH, Laftte JJ, Seneschal M, Pinon A, Camus D, Dei-Cas E. (2003). Long-term colonisation with Pneumocystis jirovecii in hospital stafs, a challenge to prevent nosocomial pneumocystosis. J Eukaryot Microbiol 50 Suppl, 614-615.
24. Ennishi D, Terui Y, Yokoyama M, Mishima Y, Takahashi S, Takeuchi K, Ikeda K, Tanimoto M, Hatake K. (2008). Increased incidence of interstitial pneumonia by CHOP combined with rituximab. Int J Hematol 87, 393-397.
25. Eriksson OE. (1994). Pneumocystis carinii, a parasite in the lungs of mammals, referred to a new family and order (Pneumocystidaceae, Pneumocystidales, Ascomycota). Systema Ascomycetum 13, 165-180.
26. Finkelman MA, Tamura H. (2007). Detection and measurement of (1-3)-ß-D-glucan with Limulus Amebocyte Lysate-based reagents. In "Te Toxicology of (1-3)-Beta-Glucans," ed. SH Young, and V Castranova). Taylor & Francis, Boca Raton.
27. Gigliotti F, Wright TW. (2005). Immunopathogenesis of Pneumocystis carinii pneumonia. Expert Rev in Molec Med 26, 1-16.
28. Goodridge HS, Wolf AJ, Underhill DM. (2009). B-glucan recognition by the innate immune system. Immunol Reviews 230, 38-50.
29. Gutierrez S, Martin-Garrido I, Leon JA, Morilla R, Rivero L, Friza V Respizalda N, Varela JM, Montes-Cano MA, Medrano JF, de la Horra C, Calderon EJ. (2008). High prevalence of Pneumocystis jirovecii colonization among young HIV-infected patients Abstract P045. International Workshop on Opportunistic Protists Boston, MA.
30. Gupta D, Zachariah A, Roppelt H, Patel AM, Gruber BL. (2008). Prophylactic antibiotic usage for Pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus on cyclophosphamide, a survey of US rheumatologists and review of the literature. J Clin Rheumatol 14, 267-272.
31. Hahn PY, Evans SE, Kottom TJ, Standing JE, Pagano RE, Limper AH. (2003). Pneumocystis carinii wall ß-glucan induces release of macrophage infammatory protein-2 from alveolar epithelia cells via lactosylceramide- mediated mechanism. J Biol Chem 278, 2043-2050.
32. Hazam S, Watanabe S, Ohashi M, Yagi M, Suzuki M, Matsuda K, Yamamoto T, Suga Y, Suga T, nakazawa S, Oka M. (2009). Efcacy of orally administered superfne dispersed lentinan. (1-3).-ß-glucan) for the treatment of advanced colorectal cancer. Anticancer Res 29, 2611-2617.
33. Hong F, Hansen RD, Yan J, Allendorf DJ, Baran J, Ostrof GR, Ross GD. (2003). B-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells (2003). Cancer Res 63, 9023-9031.
34. Hong F, Yan J, Baran JT, Allendorf DJ, Hansen RD, Ostrof GR, Xing PX, Cheung NKV, Ross GD. (2004). Mechanism by which orally administered ß-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J Immunol 173, 797-806.
35. Huang L, Morris A, Limper AH, Beck JM; ATS Pneumocystis Workshop Participants. (2006). An ofcial ATS workshop summary, Recent advances and future directions in Pneumocystis pneumonia. Proc Am Torac Soc 3, 655-664.
36. Iwanaga S. (1993). Te Limulus clotting reaction. Curr Opin Immunol 5, 74-82.
37. Jiancheng W, Minjun H, Yi-jun A, Lan S, Zengzhu G, Jianrong SS, Xixiong K. (2009). Screening Pneumocystis carinii pneumonia in non-HIV-infected immunocompromised patients using polymerase chain reaction. Diagn Microbiol Infect Dis 64, 396-401.
38. Kampf G, Assmann N, Ruden H. (1998). Direct detection of Pneumocystis carinii in outdoor air, Preliminary results of a feld study. Zentralbl Hyg Umweltmed 201, 241-249.
39. Kaur N, Mahl TC. (2008). Pneumocystis jirovecii. (carinii). pneumonia after infiximab therapy, A review of 84 cases. Dig Dis Sci 52, 1481-1484.
40. Keely SP, Stringer JR. (1996). Multi-locus genotype switching in Pneumocystis carinii sp F hominis, Evidence for reinfection. J Euk Microbiol 43, 50S.
41. Kelley CF, Checkley W, Mannino DM, Franco-Paredes C, Del Rio C, Holguin F. (2009). Trends in hospitalization for AIDS-associated Pneumocystis jirovecii pneumonia in the United States (1986-2005). Chest 136, 190-197.
42. Kerrigan AM, Brown GD. (2009). C-Type lectins and phagocytosis. Immunobiology 214, 562-575.
43. Kikkert R, Bulder I, de Groot ER, Aarden LA, Finkelman MA. (2007). Potentiation of toll-like receptor-induced cytokine production by (1-3)-ß-D-glucans, implications for the monocyte activation test. J Endotoxin Res 13, 140-149.
44. Koike R, Takeuchi T, Eguchi K, Miyasaka N. (2007). Update on the Japanese guidelines for the use of infiximab and eternacept in rheumatoid arthritis. Mod Rheumatol 17, 451-458.
45. Kolstad A, Holte H, Fossa A, Lauritzsen G, Gaustad P, Torfoss D. (2007). Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica 92, 139-140.
46. Koo S, Bryar JM, Page JH, Baden LR, Marty FM. (2009). Diagnostic performance of the (1-3)-beta-D-glucan assay for invasive fungal disease. Clin Inf Dis 49, 1650-1659.
47. Kottom TJ, Limper, AH. (2000). Cell wall assembly by Pneumocystis carinii, Evidence for a unique Gsc-1 subunit mediating ß-1,3-glucan deposition. J Biol Chem 275, 40628-40634.
48. Kovacs JA, Masur H. (2009). Evolving health efects of Pneumocystis, One hundred years of progress in diagnosis and treatment. JAMA 301, 2578-2585.
49. Kuehnhardt D, Hannemann M, Schmidt B, Heider U, Possinger K, Eucker J. (2009). Terapeutic implication of BAL in patients with neutropenia. Ann Hematol 88, 1249-1256.
50. Latouche S, Poirot J-L, Bernard C, Roux P. (1997). Study of internal transcribed spacer and mitochondrial large-subunit genes of Pneumocystis carinii hominis isolated by repeated bronchoalveo-lar lavage from human immunodefciency virus-infected patients during one or several episodes of pneumonia. J Clin Microbiol 35, 1687-1690.
51. Lautenschlager I, Lyytikainen O, Jokipii L, Jokipii A, Maiche A, Ruutu T, Tukianen P, Ruutu P. (1996). Immunodetection of Pneumocystis carinii in bronchoalveolar lavage specimens compared with methenamine silver stain. J Clin Microbiol 34, 728-730.
52. Lebron F, Vassallo R, Puri V, Limper AH. (2003). Pneumocystis carinii cell wall ß-glucans initiate macrophage infammatory responses through NF-KB activation. J Biol Chem 278, 25001-25008.
53. Lee JC, Bell DC, Guineness RM, Ahmad T. (2009). Pneumocystis jirovecii pneumonia and pneumomediastinum in an anti-TNFa naïve patient with ulcerative colitis. World J Gastroentol 15, 1897-1900.
54. Lesage G, Bussey, H. (2006). Cell wall assembly in Saccharomyces cer-evisiae. Microbiol Mol Biol Rev 70, 317-343.
55. Levy H. (1994). Comparison of Ballard catheter bronchoalveolar lavage with bronchosopic bronchoalveolar lavage. Chest 106, 1753-1756. (Pubitemid 24375137)
56. Linssen CFM, Jacobs JA, Beckers P, TemLeton KE, Bakkers J, Huijper EJ, Melchers WJG, Drent M, Vink C. (2006). Inter-laboratory comparison of three diferent real-time PCR assays for the detection of Pneumocystis jirovecii in bronchoalveolar lavage. J Med Microbiol 55, 1229-1235.
57. Marasca, G and McEvoy, M. (1986). Length of survival of patients with acquired immune defciency syndrome in the United Kingdom. Brit Med J 292, 1727-1729.
58. Matsumoto Y, Matsuda S, Tegoshi T. (1989). Yeast glucan in the cyst wall of Pneumocystis carinii. J Protozool 36, 21S-22S.
59. Matsumoto Y, Yamada M, Amagai T. (1991). Yeast glucan of Pneumocystis carinii cyst wall, an excellent target for chemotherapy. J Protozool 38, 6S-7S.
60. Medrano FJ, Montes-Cano M, Conde M, de la Horra C, Respaldiza N, Gasch A, Perez-Lozano MJ, Varela JM, Calderon EJ. (2005). Pneumocystis jirovecii in general population. Emerg Infect Dis 11, 245-250.
61. Medrano FJ, Morilla R, Garcia-Fabero N, Respaldiza N, Pinazo S, Friaza V, Cabrera J, de la Horra C, Yang R, Rivero L, Gutierrez S, Martin-Garrido I, Montes-Cano MA, Varela JM, Calderon EJ. (2008). High prevalence of Pneumocystis jirovecii colonization in the general population of southern Spain Abstract P013, International Workshop on Opportunistic Pathogens, Boston, MA.
62. Mennink-Kersten MASH, Ruegebrink D, Wasei N, Melchers WJG, Verweij PE. (2006). In vitro release by Aspergillus fumigatus of galactofuranose antigens, 1,3-ß-D-glucan, and DNA, surrogate markers used for diagnosis of invasive aspergillosis. J Clin Microbiol 44, 1711-1718.
63. Modak S, Hoehne G, Vickers A, O'Reilly RJ, Cheung NKV. (2005). Rituximab therapy of lymphoma is enhanced by orally administered (1-3) (1-4)-ß-D-glucan. Leukemia Res 29, 679-683.
64. Monnet X, Vidal-Petiot E, Osman D, Hamzaaoui O, Durrbach A, Goujard C, Miceli C, Bouree P, Richard C. (2008). Critical care management and outcome of severe Pneumocystis pneumonia in patients with and without HIV infections. Crit Care 12, R28.
65. Montes-Cano MA, de la Horra C, Dapena FJ, Mateos I, Friaza V Respaldiza N, Munoz-Lobato F, Medrano FJ, Calderoan EJ, Varela JM. (2007). Dynamic colonization by diferent Pneumocystis jirovecii genotypes in cystic fbrosis patients. Clin Microbiol Infect 13, 1008-1011.
66. Montes-Cano MA, Chabe M, Fontillon-Alberdi M, de la Horra C, Respaldiza N, Medrano FJ, Varela JM, Dei-Cas E, Calderon EJ. (2009). Vertical transmission of Pneumocystis jirovecii in humans. Emerg Infect Dis 15, 125-127.
67. Moriya K, Miura NN, Adachi Y, Ohno N. (2002). Systemic infammatory response associated with augmentation and activation of leukocytes in Candida/Indomethacin administered mice. Biol Pharm Bull 25, 816-822.
68. Morris A, Netravali M, Kling HM, Ross T, Sciurba FC, Norris KA. (2008). Relationship of Pneumocystis antibody response to severity of chronic obstructive pulmonary disease. Clin Inf Dis 47, e64-68.
69. Morris A, Sciurba FC, Norris KA. (2008). Pneumocystis, A novel pathogen in chronic obstructive pulmonary disease COPD. J Chronic Obstructive Pulmonary Dis 5, 43-51.
70. Morris A, Alexander T, Radhi S, Lucht L, Sciurba FC, Steele C, Norris KA. (2009). Airway obstruction in Pneumocystis-colonized HIV-infected outpatients. J Clin Microbiol 47, 3773-3776.
71. Nakamura H, Tateyama M, Tasato D, Haranaga S, Yara S, Higa F, Ohtsuki Y, Fujita J. (2009). Clinical utility of serum ß-D-glucan and KL-6 levels in Pneumocystis jirovecii pneumonia. Intern Med 48, 195-202.
72. Nollstadt KH, Powles MA, Fujioka H, Aikawa M, Schmatz DM. (1994). Use of (1-3)-ß-D-glucan-specifc antibody to study the cyst wall of Pneumocystis carinii and the efects of pneumocandin B0 analog L-733,560. Antmicrob Agents Chemother 38, 2258-2265.
73. Obayashi T, Negishi K, Suzuki T, Funata N. (2008). Reappraisal of the serum. (1-3).-ß-D-glucan assay for the diagnosis of invasive fungal infections-A study based upon autopsy cases from 6 years. Clin Infect Dis 46, 1864-1870.
74. Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge R, Ketchum PA, Finkelman MA, Ostrosky-Zeichner L. (2004). B-D-glucan as a diagnostic adjunct for invasive fungal infections, Validation, cutof development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 39, 199-205. (Pubitemid 38971490)
75. Odabasi Z, Paetznick VL, Rodriguez JE, Chen E, McGinnis MR, Ostrosky-Zeichner L. (2005). Diferences in beta-glucan levels in culture supernatants of a variety of fungi. Med Mycol 44, 267-272.
76. Olsson M, Sukura A, Lindberg LA, Linder E. (1996). Detection of Pneumocystis carinii DNA by fltration of air. Scand J Infect Dis 28, 279-282.
77. Olsson M, Lidman C, Latouche S, Bjorckman A, Roux P, Linder E, Wahlgren M. (1998). Identifcation of Pneumocystis carinii f sp Hominis gene sequences in fltered air in hospital environments. J Clin Micro 36, 1737-1740.
78. Ostrosky-Zeichner L, Alexander BD, Kett DH, Vazquez J, Pappas PG, Saeki F, Ketchum PA, Wingard J, Schif R, Tamura H, Finkelman MA, Rex JH. (2005). Multicenter clinical evaluation of the (1-3)-ß-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 41, 654-659.
79. Pazos C, Ponton J, Del Palacio A. (2005). Contribution of (1-3)-ß-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients, A comparison with serial screening for circulating galactomannan. J Clin Microbiol 43, 299-305.
80. Pazos C, Moragues DD, Quindos G, Ponton J, del Palacio A. (2006). Diagnostic potential of (1-3)-ß-D-glucan and anti-Candida albicans germ tube antibodies for the diagnosis and therapeutic monitoring of invasive candidiasis in neutropenic adult patients. Rev Iberoam Micol 23, 209-215.
81. Peglow SL, Smulian AG, Linke MJ, Pogue Cl, Nurre S, Crisler J, Phair J, Gold JW, Armstrong D, Walzer PD. (1990). Serologic responses to Pneumocystis carinii antigens in health and disease. J Infect Dis 161, 296-306.
82. Persat F, Ranque S, Derouin F, Michel-Nguyen A, Picot S, Sulahian A. (2008). Contribution of the (1-3)-ß-D-glucan assay for the diagnosis of invasive fungal infection. J Clin Microbiol 46, 1009-1013.
83. Pifer LL, Hughes WT, Stagno S, Woods D. (1978). Pneumocystis carinii infection, evidence for high prevalence in normal and immuno-suppressed children. Pediatrics 61, 35-41.
84. Pinlaor S, Mootsikapun P, Pinlaor P, Phunmanee A, Pipitgool V Sithithaworn P, Chumpia W, Sithithaworn J. (2004). PCR diagnosis of Pneumocystis carinii on sputum and bronchoalveolar lavage samples in immuno-compromised patients. Parasitol Res 94, 213-218.
85. Pisciulli ML, Sax PE. (2008). Use of a serum ß-glucan assay for diagnosis of HIV-related Pneumocystis jirovecii pneumonia in patients with negative microscopic examination results. Clin Infect Dis 46, 1928-1930.
86. Ponce CA, Gallo M, Bustamente R, Vargas SL. (2010). Pneumocystis colonization is highly prevalent in the autopsied lungs of the general population. Clin Inf Dis 50, 347-353.
87. Redhead SA, Cushion MT, Frenkel JK, Stringer JR. (2006). Pneumocystis and Trypanosoma cruzi, Nomenclature and Typifcations. J Euk Microbiol 53, 1-10v.
88. Respalzida N, Medrano FJ, Medrano AC, Varela JM, de la Horra C, Montes-Cano M, Wichman I, Gargallo-Viola D, Calderon EJ. (2004). High seroprevalence of Pneumocystis infection in Spanish children. Clin Microbiol Infect 10, 1029-1031.
89. Rivero L, de la Horra C, Montes-Cano MA, Rodríguez-Herrera A, Respaldiza N, Friaza V, Morilla R, Gutiérrez S, Varela JM, Medrano FJ, Calderón EJ. (2008). Pneumocystis jirovecii transmission from immunocompetent carriers to infant. Emerg Infect Dis 14, 1116-1118.
90. Rohner P, Jacomo V, Studer R, Schrenzel J, Graf J-D. (2009). Detection of Pneumocystis jirovecii by two staining methods and two quantitative PCR assays. Infection 37, 261-265.
91. Sax P, Komarow L, Finkelman MA, Grant, PM, Andersen, J, Zolopa AR. (2009). (1→3)-β-D-glucan is a promising non-invasive diagnostic test for HIV-related Pneumocystis jirovecii pneumonia Poster H-1564a Inter-Science Conference on Antimicrobial agents and Chemotherapy, San Francisco.
92. Scheicher ME, Filho JT, Vianna EO. (2003). Sputum induction, review of literature and proposal for a protocol. Sao Paulo Med J 121, 213-219.
93. Shimizu A, Oka H, Matsuda T, Ozaki S. (2005). (1→3)-β-D-glucan is a diagnostic and negative prognostic marker for Pneumocystis carinii pneumonia in patients with connective tissue disease. Clin Exp Rheum 23, 678-680.
94. Spencer L, Ukwu M, Alexander T, Valadez K, Liu L, Frederick T, Kovacs A, Morris A. (2008). Epidemiology of Pneumocystis colonization in families. Clin Infect Dis 46, 1237-1240.
95. Stringer JR. (1996). Pneumocystis carinii, What is it exactly? Clin Microbiol Rev 9, 489-498.
96. Takahashi H, Ohno N, Adachi Y, Yadomae T. (2001). Association of immunological disorders in lethal side efect of NSAIDS on β-glucan- administered mice. FEMS 31, 1-14.
97. Tomas C F, Limper AH. (2004). Pneumocystis pneumonia. NEJM 350, 2487-2498.
98. Tiley SM, Marriott DJ, Harkness JL. (1994). An evaluation of four methods for the detection of Pneumocystis carinii in clinical specimens. Pathology 26, 325-328.
99. Tokuda H, Sakai F, Yamada H, Johkoh T, Imamura A, Dohi M, Hirakata M, Yamada T, Kamatani N, Kikuchi Y, Sugii S, Takeuchi K, Goto H. (2008). Clinical and radiological features of Pneumocystis pneumonia in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis, and Pneumocystis pneumonia in acquired immunodefciency syndrome, a multicenter study. Inter Med 47, 915-923.
100. Vassallo R, Standing JE, Limper AH. (2000). Isolated Pneumocystis cari-nii cell wall glucan provokes lower respiratory tract infammatory responses. J Immunol 164, 3755-3763.
101. Wakefeld AE, Pixley FJ, Banerji S, Sinclair K, Miller RF, Moxon ER, Hopkin JM. (1990). Detection of Pneumocystis carinii with DNA amplifcation. Lancet 336, 451-453. (Pubitemid 20264212)
102. Watanabe T, Yasuoka A, Tanuma J, Yazaki H, Honda H, Tsukuda H, Honda M, Gatanaga H, Teryua K, Kikuchi Y, Oka S. (2009). Serum (1→3)-β-D-glucan as an adjunct marker for the diagnosis of Pneumocystis pneumonia in patients with AIDS. Clin Inf Dis 49, 1128-1131.
103. Weig M, Klinker H, Wilhelm M, Lemmer K, Gross U. (1996). Correlation of Pneumocystis carinii PCR with clinical diagnosis in immuno-compromised patients. Lancet 347, 1266.
104. Werner JL, Metz AE, Horn D, Schoeb TR, Hewitt MM, Schwiebert LM, Faro-Trinidade I, Brown GD, Steele C. (2009). Requisite role for the Dectin-1 beta-glucan receptor in pulmonary defense against Aspergillus fumigates. J Immunol 182, 4938-4946.
105. Williams DL, Lowman DW, Ensley HE. (2007). Introduction to the chemistry and immunobiology of β-glucans. In "Te Toxicology of (1→3)-Beta-Glucans," ed. SH Young,and V Castranova. Taylor & Francis, Boca Raton.
106. Willment JA, Gordon S, Brown GD. (2001). Characterization of the human beta-glucan receptor and its alternatively spliced forms. J Biol Chem 276, 43,818-43,823.
107. Xia Y, Veticka V, Yan Y, Hanikyrova M, Mayadas T, Ross GD. (1999). Te β-glucan-binding lectin site of mouse CR3. (CD11b/CD18). and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. J Immunol 162, 2281-2290.
108. Xia Y, Borland G, Huang J, Mizukami IF, Petty HR, Todd RF, Ross GR. (2002). Function of the lectin domain of Mac-1/complement receptor type 3 (CD11b/CD18) in regulating neutrophil adhesion. J Immunol 169, 6417-6426.
109. Yasuoka A, Tachikawa N, Shimada K, Kimura S, Oka S. (1996). (1→3)-β-D-glucan as a quantitative serological marker for Pneumocystis carinii pneumonia. Clin Diagn Lab Immunol 3, 197-199.
110. Yazaki Y, Goto N, Uchida K, Kobayashi T, Gatanaga H, Oka Shinichi. (2008). Outbreak of Pneumocystis jirovecii pneumonia is contagious to the susceptible host. Transplantation 88, 380-385.